The U.S. Food and Drug Administration has placed Astellas Pharma’s Phase I/II FORTIS trial on clinical hold after one of its study participants experienced a serious adverse event (SAE).
https://www.pharmalive.com/wp-content/uploads/2021/09/Astellas-Pauses-Dosing-of-Gene-Therapy-After-Liver-Linked-Concerns-BioSpace-9-1-21.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-06-27 10:07:592022-06-27 10:30:48More gene therapy woes for Astellas as FDA presses pause on Pompe trial
